Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Cancer chemotherapeutic agents as human teratogens.

Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, Mumm CD, Hallford HG, Mulvihill JJ.

Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):626-50. doi: 10.1002/bdra.23063. Epub 2012 Jul 31. Review.

PMID:
22851372
2.

Fetal outcome after in utero exposure to cancer chemotherapy.

Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G.

Arch Intern Med. 1992 Mar;152(3):573-6.

PMID:
1546920
3.

Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.

Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J.

Drug Saf. 2007;30(3):247-64. Review.

PMID:
17343431
4.

Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry.

Cardonick E, Usmani A, Ghaffar S.

Am J Clin Oncol. 2010 Jun;33(3):221-8. doi: 10.1097/COC.0b013e3181a44ca9.

PMID:
19745695
5.

The use of chemotherapeutic agents during pregnancy.

Sorosky JI, Sood AK, Buekers TE.

Obstet Gynecol Clin North Am. 1997 Sep;24(3):591-9. Review.

PMID:
9266580
6.

Teratogen update: evaluation of the reproductive and developmental risks of caffeine.

Christian MS, Brent RL.

Teratology. 2001 Jul;64(1):51-78. Review.

PMID:
11410911
7.

Combined chemotherapy and teratogenicity.

Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, Rosa R, Graziadio C.

Birth Defects Res A Clin Mol Teratol. 2005 Sep;73(9):634-7.

PMID:
16104005
8.

Obstetrical, fetal and postnatal effects of gestational antiblastic chemotherapy: how to counsel cancer patients.

Del Pup L, Peccatori FA, Azim HA Jr, Michieli M, Moioli M, Giorda G, Tirelli U, Berretta M.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2 Suppl):33S-46S. Review.

PMID:
23092518
9.

Drug use during pregnancy and breast-feeding. A classification system for drug information.

Berglund F, Flodh H, Lundborg P, Prame B, Sannerstedt R.

Acta Obstet Gynecol Scand Suppl. 1984;126:1-55.

PMID:
6393685
11.

Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.

Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME.

Birth Defects Res A Clin Mol Teratol. 2005 Nov;73(11):888-96.

PMID:
16163683
12.
13.
14.

Occupational exposure to anticancer drug--potential and real hazards.

Sorsa M, Hemminki K, Vainio H.

Mutat Res. 1985 Sep;154(2):135-49. Review.

PMID:
3929080
15.

Children exposed to chemotherapy in utero.

Gwyn K.

J Natl Cancer Inst Monogr. 2005;(34):69-71. Review.

PMID:
15784828
16.

Prescription drugs and pregnancy.

Webster WS, Freeman JA.

Expert Opin Pharmacother. 2003 Jun;4(6):949-61. Review.

PMID:
12783591
17.

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.

Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A.

Am J Obstet Gynecol. 2005 Mar;192(3):932-6.

PMID:
15746694
18.

Immunosuppression in pregnancy: choices for infant and maternal health.

Armenti VT, Moritz MJ, Cardonick EH, Davison JM.

Drugs. 2002;62(16):2361-75. Review.

PMID:
12396228
19.

[Cancer and pregnancy: risks of exposure to cancer chemotherapy during pregnancy].

Bavoux F, Elefant E.

J Gynecol Obstet Biol Reprod (Paris). 2004 Feb;33(1 Suppl):S29-32. Review. French.

20.

The contribution of environmental teratogens to embryonic and fetal loss.

Brent RL, Beckman DA.

Clin Obstet Gynecol. 1994 Sep;37(3):646-70. Review.

PMID:
7955651

Supplemental Content

Support Center